
Look back at our archive of previous Meet the Press blog posts. Limited time: Save 25% on NBC News subscription Get exclusive reporting, live Q&As and ad-free reading. For the latest posts from the journalists at NBC News and the NBC News Political Unit, click here. Sahil Kapur WASHINGTON — AARP, the advocacy group for Americans over fifty, is launching new cable and broadcast TV ads in West Virginia urging centrist Sen. Joe Manchin, D-W.Va.
Main Idea: Joe Manchin is facing a new AARP ad push in West Virginia aimed at pressuring him to back a budget bill that would let Medicare negotiate lower drug prices.
Key Points:
Political ad blitzes can raise campaign noise and spend millions on persuasion instead of public needs, making it harder for voters to judge the real issues.
The ads may help push lower drug prices and give households some savings if Joe Manchin backs a deal that passes.
Rate how each entity in this article affected the American people.
Primary political target of the campaign and a central figure in the reconciliation negotiations.
Central actor in the Georgia governor race and the main Republican opponent to Perdue.
Major named negotiator in the budget reconciliation talks with Manchin.
Major political organization spending heavily in support of Stacey Abrams.
Central Trump-endorsed Senate candidate discussed in the Pennsylvania primary results.
Named political figure whose endorsement of Mehmet Oz and David Perdue is central to the article’s election coverage.
Named national political figure whose endorsement and election context are discussed in the primaries.
Major outside group spending on behalf of Governor Brian Kemp.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to commentMajor political figure in the Georgia gubernatorial primary and Trump-backed candidate discussed at length.
Major candidate in the Georgia general-election context and a leading spender in the race.
Mentioned as a lobbying opponent in AARP’s push on drug prices, but not a central focus.